



## 2022 Annual Meeting Planning Committee (AMPC) Disclosures

The AMPC provides oversight and guidance on all educational activities related to the ACR Annual Meeting. Because it is not always clear what content or topic will be discussed, committee members are asked to disclose all financial relationships. Recusal is the primary mechanism for resolution. However, by the nature of committee work, the peer review process also plays a role in ensuring balance.

The following types of relationships may be deemed relevant include:

1. **Advisor or Review Panel Member**
2. **Consultant**
3. **Employee**
4. **Officer or Board Member**
5. **Grant/Research Support**
6. **Speaker/Honoraria (includes speakers bureau, symposia, and expert witness)**
7. **Independent Contractor**
8. **Ownership Interest**
9. **Royalties**
10. **Intellectual Property/Patents**
11. **Stock options or bond holdings in a for-profit corporation or self-directed pension plan**
12. **Other Financial or Material Support**

**Iannis Adamopoulos**

*Disclosure(s): Has no relevant financial relationship(s) with ineligible companies to disclose.*

**Brittany Adler, MD**

*Disclosure(s): Has no relevant financial relationship(s) with ineligible companies to disclose.*

**Salahuddin Ahmed, PhD;MSc**

*Disclosure(s): Has no relevant financial relationship(s) with ineligible companies to disclose.*

**Anca Askanase, MD, MPH**

*Disclosure(s): Amgen: 1 (Ongoing); AstraZeneca: 1 (Ongoing), 5 (Ongoing); Aurinia: 1 (Ongoing); Eli Lilly: 5 (Ongoing); GlaxoSmithKlein(GSK): 1 (Ongoing); Idorsia: 5 (Ongoing); Janssen: 5 (Ongoing); Pfizer: 5 (Ongoing); UCB: 5 (Ongoing)*

**Janet Bahr, NP**

*Disclosure(s): Abbvie: 6 (Terminated)*

**April Barnado, MD, MSc**

*Disclosure(s): Has no relevant financial relationship(s) with ineligible companies to disclose.*

\*All of the relevant financial relationships listed for these individuals have been mitigated.

**Betsy Barnes, PhD**

*Disclosure(s): Has no relevant financial relationship(s) with ineligible companies to disclose.*

**Luke Barre, MD, MPH**

*Disclosure(s): Has no relevant financial relationship(s) with ineligible companies to disclose.*

**Christie M. Bartels, MD, MS**

*Disclosure(s): Independent Grants for Learning & Change (Pfizer): 5 (Ongoing)*

**Elana Bernstein, MD, MSc**

*Disclosure(s): Boehringer Ingelheim: 5 (Ongoing); Eicos: 5 (Terminated); Kadmon: 5 (Ongoing); Pfizer: 5 (Ongoing)*

**Jill Blitz, PT**

*Disclosure(s): Has no relevant financial relationship(s) with ineligible companies to disclose.*

**Matthew Bunyard, MD**

*Disclosure(s): AbbVie: Non paid consultant (Terminated); ACAA: 6 (Terminated); American College of Rheumatology: 4 (Terminated); Astrazeneca: Non paid consultant (Terminated); Bristol-Myers Squibb: 5 (Terminated), Non paid consultant (Terminated); ChemoCentryx: 5 (Terminated); Churg-Strauss Syndrome Association: Non paid consultant (Terminated); FDA: 5 (Terminated); Genetech: 5 (Terminated); Glaxo Smith Kline: 5 (Terminated); Harvard University: 6 (Terminated); Iowa Rheumatology Society: 6 (Terminated); McGraw Hill Publishing: Associate Editor (Terminated); NIH: 5 (Terminated); RheumNow.com: 6 (Terminated); South Carolina Rheumatology Society: 6 (Terminated); Tennessee Rheumatology Society: 6 (Terminated); UCLA: 6 (Terminated); University of California San Diego: 6 (Terminated); Vasculitis Foundation: Non paid consultant (Terminated); Wiley Publishing: Book Editor (Terminated)*

**Priscilla Calvache, LCSW, MSW**

*Disclosure(s): Has no relevant financial relationship(s) with ineligible companies to disclose.*

**Laura Cappelli, MD**

*Disclosure(s): AbbVie: 2 (Terminated); Bristol-Myers Squibb: 2 (Ongoing), 5 (Ongoing); Mallinckrodt: 1 (Terminated); Tremeau Pharmaceuticals: 1 (Terminated)*

**Aimee Chen-Wiener, MSN, APRN**

*Disclosure(s): Has no relevant financial relationship(s) with ineligible companies to disclose.*

**Lisa Christopher-Stine, MD, MPH**

*Disclosure(s): AbbVie: 1 (Terminated, November 1, 2019); Kabafusion: 1 (Ongoing); Roivant/Priovant: 1 (Ongoing)*

**Colin Cox, BSc**

*Disclosure(s): Has no relevant financial relationship(s) with ineligible companies to disclose.*

**Anne Davidson, MBBS, FRACP**

*Disclosure(s): Alpine Immune Sciences: 4 (Ongoing); Viela Bio: 2 (Ongoing)*

**Eric Dein, MD, RhMSUS**

*Disclosure(s): Has no relevant financial relationship(s) with ineligible companies to disclose.*

**Michael Feely, MD**

*Disclosure(s): Has no relevant financial relationship(s) with ineligible companies to disclose.*

**Elaine Flanagan, MD, RhMSUS**

*Disclosure(s): Has no relevant financial relationship(s) with ineligible companies to disclose.*

**Elizabeth Frame, MD**

*Disclosure(s): Has no relevant financial relationship(s) with ineligible companies to disclose.*

\*All of the relevant financial relationships listed for these individuals have been mitigated.

**Tracy Frech, MD, MS**

*Disclosure(s): Has no relevant financial relationship(s) with ineligible companies to disclose.*

**Linda Hiraki, MD, FRCPC, ScD**

*Disclosure(s): Novartis: 6 (Terminated)*

**Mary Beth Humphrey, MD, PhD**

*Disclosure(s): Has no relevant financial relationship(s) with ineligible companies to disclose.*

**Rumey Ishizawar, MD, PhD**

*Disclosure(s): Has no relevant financial relationship(s) with ineligible companies to disclose.*

**Matlock Jeffries, MD, FACP, FACR**

*Disclosure(s): Has no relevant financial relationship(s) with ineligible companies to disclose.*

**April Jorge, MD**

*Disclosure(s): Has no relevant financial relationship(s) with ineligible companies to disclose.*

**Diane Kamen, MD, MS**

*Disclosure(s): Has no relevant financial relationship(s) with ineligible companies to disclose.*

**Puja Khanna, MD, MPH**

*Disclosure(s): AVALO: 5 (Ongoing); DYVE: 1 (Ongoing); Horizon: 1 (Ongoing); Selecta: 5 (Ongoing); SOBI: 1 (Ongoing)*

**Hanna Kim, MD, MS**

*Disclosure(s): Eli Lilly and Co.: drug and research support (Ongoing)*

**Minna Kohler, MD, RhMSUS**

*Disclosure(s): Lilly: 6 (Terminated, December 1, 2020); Mymee: 2 (Ongoing); Novartis: 2 (Terminated, November 1, 2020); Setpoint Medical: 5 (Ongoing); Springer Publications: 9 (Ongoing)*

**Sharon Kolasinski, MD**

*Disclosure(s): Has no relevant financial relationship(s) with ineligible companies to disclose.*

**Benjamin Korman, MD**

*Disclosure(s): Has no relevant financial relationship(s) with ineligible companies to disclose.*

**Michael LaValley, PhD**

*Disclosure(s): Has no relevant financial relationship(s) with ineligible companies to disclose.*

**Laura Lewandowski, MD**

*Disclosure(s): Has no relevant financial relationship(s) with ineligible companies to disclose.*

**Rebecca Manno, MD, MHS**

*Disclosure(s): Has no relevant financial relationship(s) with ineligible companies to disclose.*

**Zsuzsanna McMahan, MD, MHS**

*Disclosure(s): Cumberland: I help with skin biopsies for a clinical trial at Hopkins (Ongoing); Horizon: I was going to be a sub-I but did not do it as I was interested in helping with the ACR ILD Guideline Development (Terminated); Kadmon: I help with skin biopsies for a clinical trial at Hopkins (Ongoing); Mitsubishi: I help with skin biopsies for a clinical trial at Hopkins (Ongoing)*

**Maureen McMahan, MD, MS**

*Disclosure(s): Astra Zeneca: 5 (Ongoing), 6 (Ongoing); Aurinia: 2 (Ongoing), 6 (Ongoing); Eli Lilly: 2 (Ongoing); Glaxo Smith Kline: 2 (Ongoing), 5 (Ongoing), 6 (Ongoing)*

**Eyal Muscal, MD, MS**

*Disclosure(s): Has no relevant financial relationship(s) with ineligible companies to disclose.*

\*All of the relevant financial relationships listed for these individuals have been mitigated.

**Bernard Ng, MBBS, MSc, MMed**

*Disclosure(s): Has no relevant financial relationship(s) with ineligible companies to disclose.*

**Uyen-Sa Nguyen, MPH, DSc**

*Disclosure(s): Has no relevant financial relationship(s) with ineligible companies to disclose.*

**Nicole Orzechowski, DO, RhMSUS**

*Disclosure(s): Has no relevant financial relationship(s) with ineligible companies to disclose.*

**Christopher Palma, MD**

*Disclosure(s): Has no relevant financial relationship(s) with ineligible companies to disclose.*

**Christopher Phillips, MD**

*Disclosure(s): AbbVie: 5 (Ongoing)*

**Roneka Ravenell, MD**

*Disclosure(s): Has no relevant financial relationship(s) with ineligible companies to disclose.*

**Beth Resman-Targoff, PharmD;FCCP**

*Disclosure(s): Has no relevant financial relationship(s) with ineligible companies to disclose.*

**Linda Rodamaker, NP**

*Disclosure(s): Has no relevant financial relationship(s) with ineligible companies to disclose.*

**Noelle Rolle, MBBS**

*Disclosure(s): Has no relevant financial relationship(s) with ineligible companies to disclose.*

**Jillian Rose-Smith, PhD, MPH, MSW**

*Disclosure(s): Has no relevant financial relationship(s) with ineligible companies to disclose.*

**Kenneth Saag, MD, MSc**

*Disclosure(s): Amgen: 5 (Ongoing); Horizon Pharmaceuticals: 5 (Ongoing); LG Chem: 5 (Ongoing); Radius: 5 (Ongoing); SOBI: 5 (Ongoing)*

**Julie Schwartzman-Morris, MD, MS**

*Disclosure(s): Has no relevant financial relationship(s) with ineligible companies to disclose.*

**Susan Shenoi, MS, MBBS, RhMSUS**

*Disclosure(s): Pfizer: 2 (Ongoing)*

**Gregg Silverman, MD**

*Disclosure(s): Bristol-Myers Squibb(BMS): 2 (Ongoing)*

**Namrata Singh, MD, MSc**

*Disclosure(s): Has no relevant financial relationship(s) with ineligible companies to disclose.*

**Daniel Solomon, MD, MPH**

*Disclosure(s): Has no relevant financial relationship(s) with ineligible companies to disclose.*

**Joshua Stefanik, PhD, PT**

*Disclosure(s): Has no relevant financial relationship(s) with ineligible companies to disclose.*

**Tiphonie Vogel, MD, PhD**

*Disclosure(s): Novartis: 2 (Ongoing); Pfizer: 2 (Ongoing)*

**Elizabeth Wahl, MD, MA**

*Disclosure(s): Has no relevant financial relationship(s) with ineligible companies to disclose.*

**Rachel Wallwork, MD**

*Disclosure(s): Has no relevant financial relationship(s) with ineligible companies to disclose.*

\*All of the relevant financial relationships listed for these individuals have been mitigated.

**Kevin Wei, MD, PhD**

*Disclosure(s): Gilead Sciences: 5 (Ongoing);  
Mestag: 2 (Ongoing)*

**Jason Weinstein, PhD**

*Disclosure(s): Has no relevant financial  
relationship(s) with ineligible companies to  
disclose.*

**Hanna Zembrzuska, MD**

*Disclosure(s): Has no relevant financial  
relationship(s) with ineligible companies to  
disclose.*

\*All of the relevant financial relationships listed for these individuals have been mitigated.